FDA Approves ELTROMBOPAG — Dr. Reddy's Laboratories Inc.,

Dr. Reddy’s Laboratories Inc. announced the FDA approval of its oral Eltrombopag Olamine (ANDA219121), which is slated for March 16, 2026, and positions the company to capture market share in the established thrombocytopenia treatment landscape. This accretive addition to the firm’s generic portfolio is expected to bolster its revenue streams and competitive standing in the specialty therapeutics sector.